Tonix Signs a Research Agreement with University of Maryland to Develop TNX-1500 for the Prevention of Rejection in Heart Xenograft Transplantation in Animals
- Tonix collaborated with the University of Maryland to develop TNX-1500 for the prevention of rejection in xenograft transplantation in animals. Revivicor will provide genetically modified porcine hearts for UMB's preclinical studies
- TNX-1500 showed activity in preventing allograft and xenograft organ rejection and was well tolerated in the previous preclinical studies in non-human primates. The result supported an IND application and human clinical studies
- Additionally, the P-I study of TNX-1500 is expected to be initiated in Q2’23. TNX-1500 is an Fc-modified humanized mAb directed against CD40-ligand while Tonix highlighted results from 3 oral presentations at ATC 2022
Ref: Globenewswire | Image: Tonix
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.